THERAPY DOSSIER · th-b56543745a04

Pinocembrin

Nutraceutical · Pinocembrin (flavanone); no curated ChEMBL mechanism record

Evidence & regulatory context

Mechanism: Pinocembrin (flavanone); no curated ChEMBL mechanism record
Target: Not recorded
Injury models: Haemorrhage/shock
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL399910 ↗
ChEMBL max phase: 2 / 4 (development scale, not regulatory approval)
Synonyms: Pinocembrin; Dihydrochrysin
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02059785 ↗PHASE2suspended

Phase II Study of Pinocembrin Injection to Treat Ischemic Stroke

Ischemic Stroke

Enrolment: 216 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28007523 ↗2016Reported benefit

Pinocembrin protects hemorrhagic brain primarily by inhibiting toll-like receptor 4 and reducing M1 phenotype microglia.

MouseHaemorrhage/shockUnspecifiedMaleOptimal dose 5 mg/kg; a dose-dependent range was tested

Model: Collagenase-induced intracerebral haemorrhage; in vitro work used lipopolysaccharide-stimulated BV-2 cells and primary microglia

Pinocembrin dose-dependently reduced lesion volume by approximately 47.5% and reduced neurological deficits at 72 hours after collagenase-induced intracerebral haemorrhage. The optimal dose of 5 mg/kg suppressed microglial activation, reduced CD68-positive microglia and proinflammatory cytokines, a…

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…